Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 1.3 B
The data is delayed by 15 minutes.
Description: Celator Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies to treat cancer. Its proprietary drug ratio technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver enhanced anti-cancer activity. The company?s product pipeline includes CPX-351, a liposomal formulation of cytarabine:daunorubicin, which is in Phase III studies for the treatment of acute myeloid leukemia; and CPX-1, a liposomal formulation of irinotecan:floxuridine that has completed Phase II study for the treatment of colorectal cancer. Its preclinical stage product candidates comprise CPX-571, a liposomal formulation of irinotecan:cisplatin; and CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation for in vitro and in vivo study. The company was founded in 1999 and is headquartered in Ewing, New Jersey.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-48.83%||ROE||-97.4%||ROI|
|Current Ratio||8.05||Quick Ratio||Long Term Debt/Equity||0.45||Debt Ratio||0.24|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||5 M||Cash From Investing Activities||-20 K||Cash From Operating Activities||-4.49 M||Gross Profit|
|Net Profit||-4.71 M||Operating Profit||-4.38 M||Total Assets||35.5 M||Total Current Assets||33.96 M|
|Total Current Liabilities||4.22 M||Total Debt||15.17 M||Total Liabilities||17.7 M||Total Revenue|
|High 52 week||30.31||Low 52 week||1.19||Last close||30.24||Last change||0%|
|RSI||68||Average true range||2.2||Beta||0.01||Volume|
|Simple moving average 20 days||0.15%||Simple moving average 50 days||21.83%||Simple moving average 200 days|
|Performance Week||-0.03%||Performance Month||0.43%||Performance Quart||116%||Performance Half||2091.3%|
|Performance Year||-91.89%||Performance Year-to-date||0%||Volatility daily||0.1%||Volatility weekly||0.23%|
|Volatility monthly||0.47%||Volatility yearly||1.62%||Relative Volume||0%||Average Volume||2.85 M|
|New High||New Low|
2017-02-07 16:45:06 | Actinium Pharmaceuticals Is Better Than Celator
2016-12-19 09:10:00 | The Best Biopharma CEOs of 2016 Are...
2016-11-03 16:34:42 | Hercules Announces Strong Third Quarter Financial Results With $0 ...
2016-08-17 09:33:10 | RA Capital’s Top Q2 Performers; Predicts Big Things Ahead for Pharma Stocks
2016-07-14 10:06:47 | How Can Celator’s Portfolio Complement Jazz Pharmaceuticals?
2016-07-13 15:51:35 | A Look at Jazz Pharmaceuticals’ Celator Acquisition Deal
2016-07-13 15:51:21 | Why Did Jazz Fall after Celator Acquisition Announcement?
2016-07-07 13:33:42 | Steven Cohen Hits Another Home Run in Oncology
2016-06-27 08:21:00 | Why Celator Pharmaceuticals Is Up 1,610% in 2016
2016-06-14 22:09:03 | Yale Joins PTX’s Phase 1b/2 AML Clinical Trial
2016-06-13 19:00:00 | INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Celator Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
2016-06-04 09:40:00 | Why Celator Pharmaceuticals Shares Skyrocketed 100% in May
2016-06-03 09:46:59 | The market is looking for a Celator spoiler bid
2016-06-02 09:11:00 | SHAREHOLDER ALERT: Law Offices of Marc S. Henzel Announces Investigation into the proposed sales and mergers of American Capital Ltd., Celator Pharmaceuticals, Inc., Demandware Inc., FEI Company, Marketo Inc., SciQuest, Inc., Textura Corporation, Westar E
2016-06-02 09:11:00 | SHAREHOLDER ALERT: Law Offices of Marc S. Henzel Announces Investigation into the proposed sales and mergers of American Capital Ltd., Celator Pharmaceuticals, Inc., Demandware Inc., FEI Company, Marketo Inc., SciQuest, Inc., Textura Corpor
2016-06-01 15:11:08 | Jazz Securities Limited -- Moody's affirms Jazz's Ba3 CFR; Outlook to Negative
2016-06-01 10:55:00 | CPXX: Jazz Acquires Celator for $30.25 per Share
2016-04-12 19:22:09 | Investor Presentation – April 2016
2016-03-28 13:19:25 | Trending Stocks To Have On Your Watch-list Monday 3/28/16